Publication:
Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: A longitudinal prospective study nested to a population cohort.

dc.contributor.authorDel Brutto, Oscar H
dc.contributor.authorWu, Shasha
dc.contributor.authorMera, Robertino M
dc.contributor.authorCosta, Aldo F
dc.contributor.authorRecalde, Bettsy Y
dc.contributor.authorIssa, Naoum P
dc.date.accessioned2023-02-09T10:42:03Z
dc.date.available2023-02-09T10:42:03Z
dc.date.issued2021-03-01
dc.description.abstractNeurological complications of SARS-CoV-2 infection are noticed among critically ill patients soon after disease onset. Information on delayed neurological sequelae of SARS-CoV-2 infection is nil. Following a longitudinal study design, the occurrence of cognitive decline among individuals with a history of mild symptomatic SARS-CoV-2 infection was assessed. Stroke- and seizure-free Atahualpa residents aged ≥40 years, who had pre-pandemic cognitive assessments as well as normal brain magnetic resonance imaging and electroencephalogram recordings, underwent repeated evaluations 6 months after a SARS-CoV-2 outbreak infection in Atahualpa. Patients requiring oxygen therapy, hospitalization, and those who had initial neurological manifestations were excluded. Cognitive decline was defined as a reduction in the Montreal Cognitive Assessment (MoCA) score between the post-pandemic and pre-pandemic assessments that was ≥4 points greater than the reduction observed between two pre-pandemic MoCAs. The relationship between SARS-CoV-2 infection and cognitive decline was assessed by fitting logistic mixed models for longitudinal data as well as exposure-effect models. Of 93 included individuals (mean age 62.6 ± 11 years), 52 (56%) had a history of mild symptomatic SARS-CoV-2 infection. Post-pandemic MoCA decay was worse in seropositive individuals. Cognitive decline was recognized in 11/52 (21%) seropositive and 1/41 (2%) seronegative individuals. In multivariate analyses, the odds for developing cognitive decline were 18.1 times higher among SARS-CoV-2 seropositive individuals (95% confidence interval 1.75-188; p = 0.015). Exposure-effect models confirmed this association (β = 0.24; 95% confidence interval 0.07-0.41; p = 0.006). This study provides evidence of cognitive decline among individuals with mild symptomatic SARS-CoV-2 infection. The pathogenesis of this complication remains unknown.
dc.identifier.doi10.1111/ene.14775
dc.identifier.essn1468-1331
dc.identifier.pmcPMC8014083
dc.identifier.pmid33576150
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014083/pdf
dc.identifier.unpaywallURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014083
dc.identifier.urihttp://hdl.handle.net/10668/17165
dc.issue.number10
dc.journal.titleEuropean journal of neurology
dc.journal.titleabbreviationEur J Neurol
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Reina Sofía
dc.page.number3245-3253
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subjectCOVID-19
dc.subjectMontreal Cognitive Assessment
dc.subjectSARS-CoV-2
dc.subjectcognitive decline
dc.subjectcoronavirus-19
dc.subject.meshAged
dc.subject.meshCOVID-19
dc.subject.meshCognitive Dysfunction
dc.subject.meshHumans
dc.subject.meshLongitudinal Studies
dc.subject.meshMiddle Aged
dc.subject.meshProspective Studies
dc.subject.meshSARS-CoV-2
dc.titleCognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: A longitudinal prospective study nested to a population cohort.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number28
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC8014083.pdf
Size:
944.47 KB
Format:
Adobe Portable Document Format